Alle Meldungen
Folgen
Keine Meldung von Heska Corporation mehr verpassen.

07.03.2001 – 12:59

Heska Corporation

Heska Corporation to market new diagnostic product developed by Genzyme Corporation

    Fort Collins, Colorado (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA) today announced that it has obtained marketing rights to a new product for the detection of Giardia and Cryptosporidium from Genzyme Corporation. The agreement grants to Heska broad rights to market the product in the companion animal health market. Financial terms of the agreement were not disclosed.          (Photo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO )          Heska plans to market this product as a single "point-of-care" test which can be used by veterinarians in their offices for the rapid and simultaneous detection of the Giardia and Cryptosporidium parasites. The product is being designed for use with both dogs and cats, and is expected to be introduced by Heska next year following regulatory approval.          "The diseases that result from these infections can be quite serious," commented Robert Grieve, Heska's Chairman and Chief Executive Officer. "Both of these parasites can be introduced in numerous ways, including when pets drink from untreated water sources. The diseases can cause severe intestinal problems, diarrhea, reduced food intake and malnutrition. Furthermore, both of these infections are of concern because of the potential to be transmitted to people. Veterinarians need new products that can provide a rapid and accurate diagnosis of these diseases. We know of no single product currently being marketed which can provide point-of-care diagnosis of these two infections in companion animals, and we believe that our product will meet that need."          Heska discovers, develops, manufactures and markets companion animal health products, primarily for dogs, cats and horses. Heska has a sophisticated scientific effort devoted to applying biotechnology to the large and growing companion animal health market. Heska's existing state-of-the-art allergy diagnostics and immunotherapy products are sold to veterinarians for the testing and treatment of thousands of allergic cats and dogs each year. Heska also offers diagnostic and patient monitoring instrumentation and supplies, as well as pharmaceuticals, vaccines and diagnostic products in the United States and Europe to veterinarians, and operates a USDA- and FDA-licensed facility, which manufactures vaccines and pharmaceutical products.          With the exception of historical matters, this press release contains express or implied forward-looking information about Heska's and/or Genzyme's technology and potential future revenue from new products. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of Heska to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Heska's achievement of these results may be affected by many factors, including among others, the following: uncertainties regarding the regulatory approval of products prior to market introduction, uncertainties regarding the outcome of research and product development efforts by Heska and by others, uncertainties regarding the outcome of sales and marketing efforts by Heska and by others or the ability to successfully commercialise products in both the U.S. and European markets, uncertainties regarding the scope, enforceability and validity of patents and proprietary rights, which are subject to complex legal standards that vary from country to country and are subject to interpretation by administrative agencies and courts, competition, changes in business strategy or development plans, inability to market, sell or distribute products at currently projected costs and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-K for the year ended December 31, 1999 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2000.      ots Original Text Service: Heska Corporation Internet: http://www.recherche.newsaktuell.de      Contact: Ron Hendrick, Executive Vice President & CFO, ext. 4105, or Robert Grieve, Chairman & CEO, ext. 4155, both of Heska Corporation, +1 970 493 7272; or investor relations, Miriam Weber, ext. 352, or media relations, Matthew Orsagh, ext. 357, both of Noonan/Russo Communications, Inc., +1 212 696 4455, for Heska Corporation      Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO      PRN Photo Desk, +1 888-776-6555 or +1 201-369-3467      Web site: http://www.heska.com

Original-Content von: Heska Corporation, übermittelt durch news aktuell